Prognosis of intravesical bacillus calmette-guerin therapy for superficial bladder cancer by immunological urinary measurements: Statistically weighted syndromes analysis

Journal of Urology

Volumn 159, Issue 3, 1998, Pages 1054-1063

  Jackson, A M ^a   Ivshina, A V ^b   Senko, O ^b   Kuznetsova, A ^b   Sundan, A ^b   O'Donnell, M A ^b   Clinton, S ^b   Alexandroff, A B ^b   Selby, P J ^b   James, K ^b   Kuznetsov, V A ^b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b NONE

Author keywords

BCG immunotherapy; Bladder cancer; CD14; ICAM 1; Pattern recognition; Prognosis; TNF

Indexed keywords

BCG VACCINE; BIOLOGICAL MARKER; CD14 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; HUMAN TISSUE; INTRAVESICAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; SUPERFICIAL CANCER; URINE PH; URINE VOLUME;

EID: 0031905978     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63835-7     Document Type: Article

References (65)

1. Lamm, D. L.: Carcinoma in situ. Urol. Clin. N. Am., 19: 499, 1992.
2. Herr, H. W., Laudone, V. P. and Badalement, R. A.: Bacillus Calmette Guerin therapy alters the progression of superficial bladder cancer. J. Clin. Oncol., 6: 1450, 1988.
3. Utz, D. C., Farrow, G. M. and Rife, C. C.: Carcinoma in situ of the bladder. Cancer, 45: 1842, 1980.
4. Utz, D. C., Hanash, K. A. and Farrow, G. M.: The plight of the patient with carcinoma in situ of the bladder. J. Urol., 103: 160, 1970.
5. Bohle, A., Gedes, J., Ulmer, A. J., Hofstetter, A. G. and Flad, M. D.: Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of bladder wall. J. Urol., 144: 53, 1990.
6. Bettex-Galland, M., Studer, U. E. and Walz, A.: Neutrophil-activating peptide-1/interleukin-8 detection in human urine during acute bladder inflammation caused by transurethral resection of superficial cancer and bacillus Calmette-Guerin. Eur. Urol., 19: 171, 1991.
7. De Boer, E. C., De Jong, W. H. and Steerenberg, P. A.: Induction of interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer. Cancer. Immunol. Immunother., 34: 306, 1992.
8. DeMarco, R., Ensor, J. and Hasday, J.: Tumour-stimulated release of tumour necrosis factor-alpha by human monocyte derived macrophages. Cellular Immunol., 140: 304, 1992.
9. Ratliff, T. L., Haaf, E. O. and Catalona, W. J.: Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer. Clin. Immunol. Immunopathol., 40: 375, 1986.
10. Fleischmann, J. D., Toossi, Z. and Ellner, J. J.: Urinary interleukins in patients receiving intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. Cancer, 64: 1447, 1989.
11. De Jong, W. H., De Boer, E. C. and Van der Meijden, A. P.: Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guerin. Cancer. Immunol. Immunother., 31: 182, 1990.
12. Prescott, S., James, K. and Hargreave, T. B.: Radioimmunoassay detection of interferon-gamma in urine after intravesical BCG therapy. J. Urol., 144: 1248, 1990.
13. Jackson, A. M., Hawkyard, S. J. and Prescott, S.: The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical Evans BCG therapy. Cancer Immunol. Immunother., 36: 25, 1993.
14. Jackson, A. M., Alexandroff, A. B. and Gribbon, S. C.: Expression and shedding of ICAM-1 in bladder cancer and its immunotherapy. Int. J. Cancer, 55: 921, 1993.
15. Jackson, A. M., Alexandrov, A. B. and Prescott, S.: Production of urinary tumour necrosis factors and soluble tumour necrosis factor receptors in bladder cancer patients after bacillus Calmette-Guerin immunotherapy. Cancer Immunol. Immunother., 40: 119, 1995.
16. Jackson, A. M., Alexandroff, A. B. and Kelly, R. W.: Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin. Exp. Immunol., 99: 369, 1995.
17. Jackson, A. M.: Cytokines, cell adhesion molecules and bladder cancer immunotherapy. Thesis accepted for the degree of Ph.D. University of Edinburgh, 1992.
18. Hawkyard, S. J., Jackson, A. M. and James, K.: The inhibitory effects of interferon-gamma on the growth of bladder cancer cells. J. Urol., 147: 1399, 1992.
19. Jackson, A. M., Alexandroff, A. B. and Fleming, D.: Bacillus Calmette-Guerin (BCG) organisms directly alter the growth of bladder tumour cells. Int. J. Oncol., 5: 697, 1994.
20. Hawkyard, S. J., James, K. and Prescott, S.: The effects of recombinant human interferon-gamma on a panel of human bladder cancer cell lines. J. Urol., 145: 1078, 1991.
21. Jackson, A. M., Alexandroff, A. B. and Prescott, S.: Role of adhesion molecules in lymphokine activated killer cell killing of bladder cancer cells: Further evidence for a third ligand for leucocyte function associated antigen-1. Immunol., 76: 286, 1992.
22. Jackson, A. M., Alexandroff, A. B. and Prescott, S.: Adhesion molecules on bladder cancer cells: Modulation by interferon-gamma and tumour necrosis factor-alpha. J. Urol., 148: 1583, 1992.
23. Alexandroff, A. B., Jackson, A. M. and Esuvaranathan, K.: Autocrine regulation of ICAM-1 expression on bladder cancer cell lines: evidence for role of IL-1 alpha. Immunol. Letts., 40: 117, 1994.
24. Campbell, S. C., Tanabe, K. and Alexander, J. P.: Intercellular adhesion molecule-1 expression by bladder cancer cells: Functional effects. J. Urol., 151: 1385, 1994.
25. Prescott, S., James, K. and Busutill, A.: HLA-DR expression by high grade superficial bladder cancer treated with BCG. Br. J. Urol., 63: 264, 1989.
26. Jackson, A. M., Alexandroff, A. B. and McIntyre, M.: BCG immunotherapy induces ICAM-1 expression on bladder tumours. J. Clin. Path., 47: 309, 1994.
27. Torrence, R., Kavoussi, L. R., Catalona, W. J. and Ratliff, T. L.: Prognostic factors in patients treated with intravesical bacillus Calmette Guerin for superficial transitional cells carcinoma of bladder. J. Urol., 139: 941, 1988.
28. De Reijke, T. M., De Boer, E. C. and Kurth, K.: Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: Processing, stability and prognostic value. J. Urol., 155: 477, 1996.
29. Hand, D. J.: Discrimination and Classification. 1991, New-York: Wiley.
30. Zadeh, L. A.: Fuzzy sets and common sense knowledge. Cognitive Science Report. 1984, N21, Berkeley: Univ. of California.
31. Bellman, R. and Zadeh, L. A.: Decision-making in a fuzzy environment. Mgmt. Sci., 17: 141, 1970.
32. Astion, M. L. and Wilding, P.: The application of back propagation neural networks to problems in pathology and laboratory medicine. Arch. Path. Lab. Med., 116: 995, 1992.
33. Cheng, B. and Titterington, D. M.: Neural Networks: A Review from a Statistical Perspective. Statistical Sci., 9: 2, 1994.
34. Kuznetsov, V. A., Gusev, Yu.V. and Senko, O. V.: Application of novel pattern recognition method to image cytometry and morphometry data to differentiate normal and tumor cells. Proceedings of The 2nd International Workshop: Modern Methods in Analytic Morphology. April 4-5, 1994, Orlando, Florida.
35. Kuznetsov, V. A., Makalkin, I. A. and Taylor, M. A.: Nonlinear dynamics of immunogenic tumours: Parameter estimation and global bifurcations analysis. Bull. Math. Biology, 56: 295, 1994.
36. Kuznetsov, V. A.: Immune process dynamics during cancer growth. Moscow: Nauka, 1992.
37. Ivshina, A. V., Kuznetsov, V. A. and Kuznetsova, A. V.: Lymphocyte phenotype in the blood for estimation of tumour volume and their vascularisation in patients with osteosarcoma. Immunologiya. 6: 56, 1995.
38. Zadeh, L. A.: Fuzzy sets. Inform. Cont., 8: 338, 1965.
39. Kuznetsov, V. A., Trubcheninova, L. P., Derevnina, N. A. and Voronov, L. N.: Immune homeostasis disturbances in patients with gastrointestinal cancer. Oncology Questions, 34: 673, 1988.
40. Kuznetsov, V. A., Ivshina, A. V. and Senko, O. V.: Syndrome approach for computer recognition of fuzzy systems and its application to immunological diagnostics and prognosis of human cancer. Mathl. Comput. Modelling., 21: 92, 1996.
41. Bongard, M. M.: The Recognition Problem. Moscow: Nauka, 1967.
42. Zhuravlev, YuI., Gurevitch, I. B. and Ilyinsky, S. V.: Development and investigation of the mathematical and computational basis for a system of information technologies of pattern recognition and image understanding. Pattern Recognition and Image Analysis, 3: 266, 1993.
43. Karp, B. P. and Kunin, P. E.: Construction of decisive rule for solution of the problem of alternative diagnostics by the conjunction selection and directed training method. In: Automation: Organization, Diagnostics. Moscow: Nauka, 339, 1971.
44. Kuznetsov, V. A., Senk̀o, O. V. and Kuznetsova, A. V.: Recognition of the fuzzy systems by the statistical weighted syndromes method and its application to immuno-hematology characteristics of a normal and of the chronic pathology. Chemical Physics, in press.
45. Mueller, B. U., Zeichner, S. L., Heath-Chiozzi, M., Kuznetsov, V. A., Pizzo, P. A. and Dimitrov, D. S.: Kinetics of initial response to new anti-HIV-1 therapy in pediatric patients and correlations with long-term drug efficacy. Science, 1997 (submitted).
46. Efron, B. and Gong, G.: A leisurely look at the bootstrap, the Jack-knife. Amer. Statistician, 37: 36, 1983.
47. Vapnik, V. P., Glazkova, T. G. and Kaschejev, V. A.: Algorithms and dependence reconstruction programs. Moscow: Nauka, 1984.
48. Senk̀o, O. V.: The algorithm of prognosis, based on the procedure of voting by system of boxes on multidimensional space. Pattern Recogn. Image Analysis, 3: 283, 1993.
49. Ratliff, T. L., Gillen, D. and Catalona, W. J.: Requirement of a thymus dependent immune response for BCG-mediated antitumour activity. J. Urol., 137: 155, 1987.
50. Fujita, K., Ikarashi, H. and Takakura, K.: Prolonged disease free period in patients with advanced epithelail ovarian cancer after adoptive transfer of tumour infiltrating lymphocytes. Clin. Cancer. Res., 1: 501, 1995.
51. Weinstein, J. N., Kohn, K. W. and Grever, M. R.: Neural computing in cancer drug devopment: Predicting mechanisms of action. Science, 258: 447, 1992.
52. Beutler, B. and Cerami, A.: The biology of cachectin/TNF-a primary mediator of the host response. Ann. Rev. Immunol., 7: 625, 1989.
53. Jackson, A. M., Alexandroff, A. B. and Prescott, S.: Adhesion molecules on bladder cancer cells: Modulation by interferongamma and tumour necrosis factor-alpha. J. Urol., 148: 1583, 1992.
54. Jackson, A. M., Alexandroff, A. B. and McIntyre, M.: BCG immunotherapy induces ICAM-1 expression on bladder tumours. J. Clin. Pathol., 47: 309, 1994.
55. Prescott, S., James, K. and Busutill, A.: HLA-Dr expression by high grade superficial bladder cancer treated with BCG. Br. J. Urol., 63: 264, 1989.
56. Jackson, A. M., Alexandroff, A. B. and Prescott, S.: Role of adhesion molecules in lymphokine activated killer cell killing of bladder cancer cells: further evidence for a third ligand for leucocyte function associated antigen-1. Immunol., 72: 286, 1992.
57. Lattime, E. C., Gomella, L. G. and McCue, P. A.: Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. Cancer Res., 52: 4286, 1992.
58. Harning, R., Mainolfi, E. and Bystryn, J-C: Serum levels of circulating intercellular adhesion molecule-1 in human malignant melanoma. Cancer Res., 51: 5003, 1991.
59. Young, D. G., Jackson, A. M. and James, K.: Purification and characterization of soluble intercellular adhesion molecule-1 (sICAM-1) and its effect on cell-mediated cytolysis of tumour cells. Int. J. Oncol., 10: 827, 1997.
60. Wright, S. D., Ramos, R. A. and Tobias, P. S.: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science, 249: 1431, 1990.
61. Hailmann, E., Lichenstein, H. S. and Wurfel, M. M.: Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J. Exp. Med., 179: 269, 1994.
62. Cavaillon, J. M., Fitting, C. and Haffner-Cavillon, N.: Cytokine response by monocytes and macrophages to free and lipoprotein-bound lipopolysaccharide. Infect. Immun., 58: 2375, 1990.
63. Wurfel, M. M., Hailman, E. and Wright, S. D.: Soluble CD14 acts as a shuttle in the neutralisation of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J. Exp. Med., 81: 1743, 1995.
64. Sundan, A., Gullstein-Jahr, T. and Otterlei, M.: Soluble CD14 from urine copurifies with a potent inducer of cytokines. Eur. J. Immunol., 24: 1779, 1994.
65. Frey, E. A., Miller, D. S. and Gullstein-Jahr, T.: Soluble CD14 participates in the response of cells to lipopolysaccharide. J. Exp. Med., 176: 1665, 1992.